Skip to main content


We're creating a new version of this page. See preview

Volume 9 Supplement 2

AIDS Vaccine 2012

  • Poster presentation
  • Open Access

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Retrovirology20129 (Suppl 2) :P327

  • Published:


  • Vesicular Stomatitis Virus
  • Immunoprecipitation Study
  • 4E10 Monoclonal Antibody
  • Vector Modification
  • Small Animal Study


The HIV-neutralizing activity of monoclonal antibodies 2F5, 4E10, and Z13 have shown that the membrane-proximal external region (MPER) of HIV Env is an important vaccine target, but development of an immunogen that elicits similar virus-neutralizing antibody responses against the MPER from a wide range of subtypes has been difficult to achieve. It has been proposed that a MPER immunogen must be membrane-associated to adopt the conformation needed to elicit broadly neutralizing antibodies, and accordingly, we have developed Vesicular Stomatitis Virus(VSV) Vectors that express membrane-anchored MPER epitopes.


Replication-competent and single-cycle VSV vectors have been developed that express a truncated VSV G protein (G-Stem) in which the natural G ectodomain is replaced with MPER sequence (GStemMPER). The nucleotide sequence of GStemMPER has been optimized by computer based algorithms to ensure genetic stability. Several VSV vector modifications are also introduced for directing immune responses towards MPER rather than G. Those strategies include relocation of GStemMPER and VSV G glycoprotein to achieve maximal MPER expression while minimize the anti-vector immunity, incorporation of different VSV G serotypes and pseudotyping single- cycle VSV vectors with various types of glycoproteins.


Western blot analysis confirmed expression of MPER epitopes. Assessment by FACS showed the cell surface MPER being recognized by 2F5 and 4E10 monoclonal antibodies. Immunoprecipitation study further proved incorporation of MPER into viral particles.


Multiple VSV-GStemMPER vectors are being evaluated in small animal studies to compare their immunogenicity and whether the membrane-anchored form of the MPER immunogen elicits humoral responses with a broad range of HIV neutralizing activity.

Authors’ Affiliations

International AIDS Vaccine Initiative, Brooklyn, NY, USA


© Yuan et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.